Though no one in her family was a physician, Christine Seidman always wanted to be a doctor. But the word had a slightly different meaning for her than it does for most. “To me, that was a person who was medically trained and took care of sick people, but who also really understood why they got sick…Some people think you’re a physician or a scientist. To me, they’re synonymous. I still think that.” Seidman—who goes by Kricket (thanks to a young cousin who couldn’t pronounce “Christine”)—met her husband and research partner, Jon, when they were both undergraduates at Harvard. “We had a lab research project that we had to design and have approved. My group’s project was not approved. So they split up our group and reassigned us to other projects, and I got assigned to Jon’s group.”
The two were married during Seidman’s junior year. After graduation and medical school, Seidman headed to Johns Hopkins for her residency and internship “because it spoke science to me.” She was there for three years before moving to Boston, where she did a cardiology fellowship at Massachusetts General Hospital before finishing her training in Baltimore. At MGH, Seidman worked with a group led by the late Edgar Haber, trying to isolate and clone the genes for adrenergic receptors, which are important in cardiovascular physiology. She then became interested in atrial natriuretic peptide, or ANP. Released by the heart, ANP regulates salt and water in the bloodstream to reduce blood pressure. A partial amino acid sequence of this natriuretic peptide had just been published, and Seidman was intrigued; studying ANP had broad implications for treatment of high blood pressure. “As a cardiologist, you think this might cure hypertension.” She moved to her husband’s lab at Harvard Medical School, where she cloned the ANP cDNA and gene. The two have worked together ever since, studying the effects of genetic variation in heart disease. In 1998, she began studying disorders of heart muscle. Seidman’s work began with familial hypertrophic cardiomyopathy (HCM), which increases heart thickness and predisposes to the development of heart failure and sudden death. HCM is the most common cause of sudden death on the athletic field; it also affects many more people than originally thought. Seidman used genetic approaches to discover mutations that altered proteins involved in heart muscle contraction. This work enabled the development of models that can help researchers understand the mechanisms by which mutations cause disease. The work also allowed for gene-based diagnosis of HCM. Seidman’s group also has identified gene mutations that cause dilated cardiomyopathy and congenital heart malformations. To understand how gene mutations affect heart structure and function, Seidman’s laboratory does much of their work in mouse models. “If you know that a gene abnormality causes disease, you ought to be able to stick that gene into a cell and figure out the pathways it affects and what it does. But we don’t have any cell lines in cardiology. So we put the genes into mice and let them get heart disease and then study the heart.”
page 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |> NEXT
> download 2013 newsletter PDF
> download 2009 newsletter PDF
> view 2007 newsletter